May 18, 2026 08:31AM
May 18, 2026 08:30AM
May 7, 2026 08:30AM
May 7, 2026 08:30AM
May 5, 2026 08:31AM
May 5, 2026 08:30AM
Apr 13, 2026 08:30AM Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Nov 12, 2025 08:30AM
Aug 11, 2025 08:45AM
Aug 11, 2025 08:45AM
Jul 16, 2025 08:39AM
Jul 16, 2025 08:39AM
May 12, 2025 08:30AM
Mar 27, 2025 08:33AM Oragenics (OGEN) Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Mar 27, 2025 08:30AM
Mar 6, 2025 09:30AM
Mar 6, 2025 09:30AM
Oct 9, 2024 07:30AM
Oct 9, 2024 07:30AM
Oct 8, 2024 08:45AM
Aug 21, 2024 08:45AM Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Aug 16, 2024 04:31PM
Aug 16, 2024 04:30PM
Aug 14, 2024 08:30AM
Aug 12, 2024 08:31AM
Aug 12, 2024 08:30AM
Aug 8, 2024 08:45AM
Aug 8, 2024 08:45AM Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Jul 10, 2024 08:07AM
Jul 10, 2024 08:00AM
Jun 27, 2024 08:32AM
Jun 27, 2024 08:30AM
May 22, 2024 08:04AM
May 22, 2024 08:00AM
May 17, 2024 08:00AM Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
May 16, 2024 08:00AM
May 7, 2024 08:00AM
Mar 18, 2024 07:07AM
Mar 18, 2024 07:00AM
Mar 5, 2024 07:45AM
Mar 5, 2024 07:45AM
Feb 27, 2024 04:33PM Oragenics (OGEN) Announces Proposed Public Offering
Feb 27, 2024 04:33PM
Feb 12, 2024 04:41PM
Feb 12, 2024 04:41PM
Feb 5, 2024 08:04AM
Feb 5, 2024 08:00AM
Jan 2, 2024 07:30AM
Nov 2, 2023 07:04AM Oragenics (OGEN) Issues Update to Shareholders
Nov 2, 2023 07:00AM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All